Literature DB >> 20531016

Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Mark D Hicar1, Xuemin Chen, Bryan Briney, Jason Hammonds, Jaang-Jiun Wang, Spyros Kalams, Paul W Spearman, James E Crowe.   

Abstract

Monomeric HIV envelope vaccines fail to elicit broadly neutralizing antibodies or to protect against infection. Neutralizing antibodies against HIV bind to native functionally active Env trimers on the virion surface. Gag-Env pseudovirions recapitulate the native trimer and could serve as an effective epitope presentation platform for study of the neutralizing antibody response in HIV-infected individuals. To address if pseudovirions can recapitulate native HIV virion epitope structures, we carefully characterized these particles, concentrating on the antigenic structure of the coreceptor binding site. By blue native gel shift assays, Gag-Env pseudovirions were shown to contain native trimers that were competent for binding to neutralizing monoclonal antibodies. In enzyme-linked immunosorbent assay, pseudovirions exhibited increased binding of known CD4-induced antibodies after addition of CD4. Using flow cytometric analysis, fluorescently labeled pseudovirions specifically identified a subset of antigen-specific B cells in HIV-infected subjects. Interestingly, the sequence of one of these novel human antibodies, identified during cloning of single HIV-specific B cells and designated 2C6, exhibited homology to mAb 47e, a known anti-CD4-induced coreceptor binding site antibody. The secreted monoclonal antibody 2C6 did not bind monomeric gp120, but specifically bound envelope on pseudovirions. A recombinant form of the antibody 2C6 acted as a CD4-induced epitope-specific antibody in neutralization assays, yet did not bind monomeric gp120. These findings imply specificity against a quaternary epitope presented on the pseudovirion envelope spike. These data demonstrate that Gag-Env pseudovirions recapitulate CD4 and coreceptor binding pocket antigenic structures and can facilitate identification of B-cell clones that secrete neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20531016      PMCID: PMC2930513          DOI: 10.1097/QAI.0b013e3181dc98a3

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  49 in total

1.  Detection and enumeration of circulating HIV-1-specific memory B cells in HIV-1-infected patients.

Authors:  Jean-Michel Fondere; Marie-France Huguet; Anna Macura-Biegun; Vincent Baillat; Viviane Ohayon; Jacques Reynes; Jean-Pierre Vendrell
Journal:  J Acquir Immune Defic Syndr       Date:  2004-02-01       Impact factor: 3.731

2.  In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.

Authors:  Maria Luisa Visciano; Michael Tuen; Miroslaw K Gorny; Catarina E Hioe
Journal:  Virology       Date:  2007-12-04       Impact factor: 3.616

3.  Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines.

Authors:  Jason Hammonds; Xuemin Chen; Xiugen Zhang; Francis Lee; Paul Spearman
Journal:  Vaccine       Date:  2007-09-25       Impact factor: 3.641

Review 4.  Humoral immunity to HIV-1: neutralization and beyond.

Authors:  M Huber; A Trkola
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

5.  Immunodominance of the VH1-46 antibody gene segment in the primary repertoire of human rotavirus-specific B cells is reduced in the memory compartment through somatic mutation of nondominant clones.

Authors:  Cuixia Tian; Grace K Luskin; Kevin M Dischert; James N Higginbotham; Bryan E Shepherd; James E Crowe
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

6.  Infant and adult human B cell responses to rotavirus share common immunodominant variable gene repertoires.

Authors:  Jörn-Hendrik Weitkamp; Nicole Kallewaard; Koichi Kusuhara; Elizabeth Bures; John V Williams; Bonnie LaFleur; Harry B Greenberg; James E Crowe
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

7.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

Authors:  Zhen-Yu J Sun; Kyoung Joon Oh; Mikyung Kim; Jessica Yu; Vladimir Brusic; Likai Song; Zhisong Qiao; Jia-huai Wang; Gerhard Wagner; Ellis L Reinherz
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

8.  A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

Authors:  Emma T Crooks; Penny L Moore; Michael Franti; Charmagne S Cayanan; Ping Zhu; Pengfei Jiang; Robbert P de Vries; Cheryl Wiley; Irina Zharkikh; Norbert Schülke; Kenneth H Roux; David C Montefiori; Dennis R Burton; James M Binley
Journal:  Virology       Date:  2007-06-19       Impact factor: 3.616

9.  Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.

Authors:  Farley Cleghorn; Jean W Pape; Mauro Schechter; Courtenay Bartholomew; Jorge Sanchez; Noreen Jack; Barbara J Metch; Marianne Hansen; Mary Allen; Huyen Cao; David C Montefiori; Georgia D Tomaras; Sanjay Gurunathan; Donna J Eastman; Regina F do Lago; Sonic Jean; Javier R Lama; Dale N Lawrence; Peter F Wright
Journal:  J Acquir Immune Defic Syndr       Date:  2007-10-01       Impact factor: 3.731

Review 10.  Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein.

Authors:  George Lin; Peter L Nara
Journal:  Curr HIV Res       Date:  2007-11       Impact factor: 1.581

View more
  26 in total

Review 1.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

2.  HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 3.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

4.  Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.

Authors:  Evan M Cale; Jason Gorman; Nathan A Radakovich; Ema T Crooks; Keiko Osawa; Tommy Tong; Jiaqi Li; Raju Nagarajan; Gabriel Ozorowski; David R Ambrozak; Mangai Asokan; Robert T Bailer; Anthony K Bennici; Xuejun Chen; Nicole A Doria-Rose; Aliaksandr Druz; Yu Feng; M Gordon Joyce; Mark K Louder; Sijy O'Dell; Courtney Oliver; Marie Pancera; Mark Connors; Thomas J Hope; Thomas B Kepler; Richard T Wyatt; Andrew B Ward; Ivelin S Georgiev; Peter D Kwong; John R Mascola; James M Binley
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

5.  Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.

Authors:  Sudhir Pai Kasturi; Pamela A Kozlowski; Helder I Nakaya; Matheus C Burger; Pedro Russo; Mathew Pham; Yevgeniy Kovalenkov; Eduardo L V Silveira; Colin Havenar-Daughton; Samantha L Burton; Katie M Kilgore; Mathew J Johnson; Rafiq Nabi; Traci Legere; Zarpheen Jinnah Sher; Xuemin Chen; Rama R Amara; Eric Hunter; Steven E Bosinger; Paul Spearman; Shane Crotty; Francois Villinger; Cynthia A Derdeyn; Jens Wrammert; Bali Pulendran
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

6.  Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James E Robinson; Mary Barnes; Cristian Apetrei; James M Binley
Journal:  Virology       Date:  2014-05       Impact factor: 3.616

Review 7.  Structure-based vaccine design in HIV: blind men and the elephant?

Authors:  Robert Pejchal; Ian A Wilson
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

8.  Alterations of the B-cell response by HIV-1 replication.

Authors:  Xiaoying Shen; Georgia D Tomaras
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

9.  Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.

Authors:  Mark D Hicar; Xuemin Chen; Spyros A Kalams; Hakimuddin Sojar; Gary Landucci; Donald N Forthal; Paul Spearman; James E Crowe
Journal:  Mol Immunol       Date:  2015-12-31       Impact factor: 4.407

Review 10.  Induction of immunity to human immunodeficiency virus type-1 by vaccination.

Authors:  M Juliana McElrath; Barton F Haynes
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.